To investigate whether patients with ACPA-negative (ACPA–) and ACPA-positive (ACPA+) rheumatoid arthritis (RA) exhibit distinct immune and metabolic profiles in blood, using integrative proteomic and metabolomic analyses. This evidence concerns the gene PRTN3 and rheumatoid arthritis.